Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Bögemann

Showing results (1-10 of 99) with videos related to

Pageof 10
Sort By:
Oncology Research and Treatment|April 9, 2019
SPARTAN: Gezielte Analyse der ResistenzenMartin Bögemann
Urologie (Heidelberg, Germany)|August 4, 2022
[Systematic action-Emergencies in systemic cancer therapy!]Martin Bögemann
Aktuelle Urologie|April 21, 2021
[Non-metastatic castration-resistant prostate cancer (M0CRPC) - Apalutamide in high-risk M0CRPC: case reports from the SPARTAN study and the apalutamide compassionate use program]Philipp Spiegelhalder, Martin Bögemann
European Journal of Nuclear Medicine and Molecular Imaging|October 5, 2016
<sup>177</sup>Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of responseKambiz Rahbar, Martin Bögemann, Hojjat Ahmadzadehfar
BMC Cancer|July 10, 2025
Utility of the prostest to predict and monitor response to chemotherapy in metastatic Castration-Resistant prostate cancer: A prospective pilot studyKambiz Rahbar, Katrin Schlack, Martin Bögemann
Aktuelle Urologie|July 28, 2021
[Second/Third-Line Therapie nach Versagen von Docetaxel bei metastasiertem Prostatakarzinom (mCRPC)]Heidrun Rexer, Marc-Oliver Grimm, Martin Bögemann
Cancers|July 24, 2021
Evolving Castration Resistance and Prostate Specific Membrane Antigen Expression: Implications for Patient ManagementKatharina Kessel, Christof Bernemann, Martin Bögemann, et al.
Prostate Cancer and Prostatic Diseases|February 9, 2021
Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitorsFred Saad, Martin Bögemann, Kazuhiro Suzuki, et al.
Oncology Research and Treatment|April 3, 2017
[Not Available]Christof Bernemann, Martin Bögemann, Julie Steinestel, et al.
Nuklearmedizin. Nuclear Medicine|January 12, 2017
Diagnostic value of additional <sup>68</sup>Ga-PSMA-PET before <sup>223</sup>Ra-dichloride therapy in patients with metastatic prostate carcinomaAxel Bräuer, Kambiz Rahbar, Julia Konnert, et al.
Pageof 10

Showing results (1-10 of 99) with videos related to

Sort By:
Pageof 10
Oncology Research and Treatment|April 9, 2019
SPARTAN: Gezielte Analyse der ResistenzenMartin Bögemann
Urologie (Heidelberg, Germany)|August 4, 2022
[Systematic action-Emergencies in systemic cancer therapy!]Martin Bögemann
Aktuelle Urologie|April 21, 2021
[Non-metastatic castration-resistant prostate cancer (M0CRPC) - Apalutamide in high-risk M0CRPC: case reports from the SPARTAN study and the apalutamide compassionate use program]Philipp Spiegelhalder, Martin Bögemann
European Journal of Nuclear Medicine and Molecular Imaging|October 5, 2016
<sup>177</sup>Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of responseKambiz Rahbar, Martin Bögemann, Hojjat Ahmadzadehfar
BMC Cancer|July 10, 2025
Utility of the prostest to predict and monitor response to chemotherapy in metastatic Castration-Resistant prostate cancer: A prospective pilot studyKambiz Rahbar, Katrin Schlack, Martin Bögemann
Aktuelle Urologie|July 28, 2021
[Second/Third-Line Therapie nach Versagen von Docetaxel bei metastasiertem Prostatakarzinom (mCRPC)]Heidrun Rexer, Marc-Oliver Grimm, Martin Bögemann
Cancers|July 24, 2021
Evolving Castration Resistance and Prostate Specific Membrane Antigen Expression: Implications for Patient ManagementKatharina Kessel, Christof Bernemann, Martin Bögemann, et al.
Prostate Cancer and Prostatic Diseases|February 9, 2021
Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitorsFred Saad, Martin Bögemann, Kazuhiro Suzuki, et al.
Oncology Research and Treatment|April 3, 2017
[Not Available]Christof Bernemann, Martin Bögemann, Julie Steinestel, et al.
Nuklearmedizin. Nuclear Medicine|January 12, 2017
Diagnostic value of additional <sup>68</sup>Ga-PSMA-PET before <sup>223</sup>Ra-dichloride therapy in patients with metastatic prostate carcinomaAxel Bräuer, Kambiz Rahbar, Julia Konnert, et al.
Pageof 10